6.
Wang T, Wei J, Sabatini D, Lander E
. Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2013; 343(6166):80-4.
PMC: 3972032.
DOI: 10.1126/science.1246981.
View
7.
Shalem O, Sanjana N, Hartenian E, Shi X, Scott D, Mikkelson T
. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2013; 343(6166):84-87.
PMC: 4089965.
DOI: 10.1126/science.1247005.
View
8.
Guieze R, Liu V, Rosebrock D, Jourdain A, Hernandez-Sanchez M, Zurita A
. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019; 36(4):369-384.e13.
PMC: 6801112.
DOI: 10.1016/j.ccell.2019.08.005.
View
9.
Wang T, Birsoy K, Hughes N, Krupczak K, Post Y, Wei J
. Identification and characterization of essential genes in the human genome. Science. 2015; 350(6264):1096-101.
PMC: 4662922.
DOI: 10.1126/science.aac7041.
View
10.
Tsherniak A, Vazquez F, Montgomery P, Weir B, Kryukov G, Cowley G
. Defining a Cancer Dependency Map. Cell. 2017; 170(3):564-576.e16.
PMC: 5667678.
DOI: 10.1016/j.cell.2017.06.010.
View
11.
McDonald 3rd E, de Weck A, Schlabach M, Billy E, Mavrakis K, Hoffman G
. Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell. 2017; 170(3):577-592.e10.
DOI: 10.1016/j.cell.2017.07.005.
View
12.
Hartenian E, Doench J
. Genetic screens and functional genomics using CRISPR/Cas9 technology. FEBS J. 2015; 282(8):1383-93.
DOI: 10.1111/febs.13248.
View
13.
Martin S, Reutelingsperger C, McGahon A, Rader J, van Schie R, LaFace D
. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995; 182(5):1545-56.
PMC: 2192182.
DOI: 10.1084/jem.182.5.1545.
View
14.
Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C
. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995; 184(1):39-51.
DOI: 10.1016/0022-1759(95)00072-i.
View
15.
Zargarian S, Shlomovitz I, Erlich Z, Hourizadeh A, Ofir-Birin Y, Croker B
. Phosphatidylserine externalization, "necroptotic bodies" release, and phagocytosis during necroptosis. PLoS Biol. 2017; 15(6):e2002711.
PMC: 5501695.
DOI: 10.1371/journal.pbio.2002711.
View
16.
Jourdain A, Begg B, Mick E, Shah H, Calvo S, Skinner O
. Loss of LUC7L2 and U1 snRNP subunits shifts energy metabolism from glycolysis to OXPHOS. Mol Cell. 2021; 81(9):1905-1919.e12.
PMC: 8314041.
DOI: 10.1016/j.molcel.2021.02.033.
View
17.
Doench J, Fusi N, Sullender M, Hegde M, Vaimberg E, Donovan K
. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016; 34(2):184-191.
PMC: 4744125.
DOI: 10.1038/nbt.3437.
View
18.
Yang X, Boehm J, Yang X, Salehi-Ashtiani K, Hao T, Shen Y
. A public genome-scale lentiviral expression library of human ORFs. Nat Methods. 2011; 8(8):659-61.
PMC: 3234135.
DOI: 10.1038/nmeth.1638.
View
19.
Robinson B, Buncic J, Wallace D
. Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts. Biochem Med Metab Biol. 1992; 48(2):122-6.
DOI: 10.1016/0885-4505(92)90056-5.
View
20.
Li W, Xu H, Xiao T, Cong L, Love M, Zhang F
. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014; 15(12):554.
PMC: 4290824.
DOI: 10.1186/s13059-014-0554-4.
View